Denali Therapeutics Inc. received $200.0 million in gross proceeds from Royalty Pharma on March 27, 2026, following the accelerated FDA approval of tividenofusp alfa.
Key takeaways
The company received $200.0 million in gross proceeds from Royalty Pharma on March 27, 2026.
The funding followed the accelerated FDA approval of tividenofusp alfa on March 24, 2026.
The proceeds are related to the closing of transactions under a synthetic royalty funding agreement.
The agreement was previously disclosed in a Form 8-K filed on December 4, 2025.